HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Krylova, S. Articles by Benishin, C. G. Search for Related Content PubMed PubMed Citation Articles by Krylova, S. Articles by Benishin, C. G. Related Collections Lipids, Lipoproteins, and Cardiovascular Risk Factors Endocrinology and Metabolism

Generation, Characterization, and Use of Monoclonal Antibodies against Parathyroid Hypertensive Factor

¹ CV Technologies Inc., Edmonton, Alberta, T6N 1E5 Canada

² Department of Physiology, University of Alberta, Edmonton, Alberta, T6G 2H7 Canada

³ Division of Endocrinology, University of Alberta, Edmonton, Alberta, T6G 2S2 Canada

^aauthor for correspondence: e-mail christina.benishin@ualberta.ca

The first 300 words of the full text of this article appear below.

Parathyroid hypertensive factor (PHF) may be useful as a diagnostic marker of salt-sensitive, low-renin hypertension. PHF was discovered in the plasma of salt-sensitive hypertensive humans (1) and was also found to be increased in spontaneously hypertensive rats, DOCA-salt-hypertensive rats, and Dahl-salt-sensitive rats, but not in two-kidney one-clip rats or in Dahl-salt-insensitive rats (2)(3). Studies on the mechanism of PHF action indicate that this substance acts directly on vascular smooth muscle cells to enhance Ca²⁺ influx (4), likely associated with depolarization of the plasma membrane by inhibition of voltage-gated K+ channels (5). Together these actions will sensitize vascular tissues to other vasoconstrictors, such as norepinephrine and angiotensin II (6). PHF may therefore be a causative factor in the development of hypertension in some individuals. It was found that PHF-positive (salt-sensitive) patients respond best to calcium channel blockers and diuretics and that PHF-negative patients respond better to angiotensin-converting enzyme inhibitors and beta blockers (7). Recently, an enzyme immunoassay for detection of PHF in human plasma has been reported that uses anti-PHF oligoclonal antibodies (8). The present study describes the further development, characterization, and clinical application of monoclonal antibodies (MAbs) against PHF.

Male BALB/c mice were immunized with partially purified PHF (9) prepared from medium harvested from cultured parathyroid glands of spontaneously hypertensive rats, as was described previously (10). Splenocytes were harvested and fused with SP/0-2 myeloma cells by standard procedures (11). The recloning procedure involved limiting-dilution conditions in 96-well plates (0.3 cells/well).

The bovine serum albumin (BSA) conjugate of PHF was synthesized by standard procedures (12) and used in a direct ELISA for anti-PHF antibodies. Microtiter plates were coated with BSA-PHF (100 µL/well; 1:2000 dilution). After the plates . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				A. Rybczynska, A. Lehmann, A. Jurska-Jasko, K. Boblewski, C. Orlewska, H. Foks, and K. Drewnowska Hypertensive effect of calcilytic NPS 2143 administration in rats. J. Endocrinol., October 1, 2006; 191(1): 189 - 195. [Abstract] [Full Text] [PDF]